Disease relevance of Keratomileusis, Laser In Situ

• This may be helpful in evaluating factors that contribute to corneal ectasia after LASIK for myopia and hyperopia [1].
• Laser in situ keratomileusis for moderate and high myopia and myopic astigmatism [2].
• PARTICIPANTS: Three patients who underwent LASIK for correction of myopia during July and August 1998 and had bacterial keratitis develop after surgery [3].
• CONCLUSIONS: Significant risk factors for the development of ectasia after LASIK include high myopia, forme fruste keratoconus, and low RSB [4].
• METHODS: The study comprised 30 eyes of 15 consecutive patients with accommodative or partially accommodative esotropia who met eligibility requirements and had bilateral LASIK using the Alcon Summit Autonomous LADARVision excimer laser to correct a refractive error after January 2001 [5].

High impact information on Keratomileusis, Laser In Situ

• METHODS: In 215 eyes of 117 patients (age, 33.2 +/- 8.3 years) undergoing LASIK for myopia of -1.25 to -13.5 D (-5.28 +/- 2.55 D), ocular wavefront aberrations and contrast sensitivity function were determined before and 1 month after surgery [6].
• The induced changes in AULCSF by LASIK showed significant correlations with changes in total higher-order (Pearson r=-0.221, P=0.003), coma-like (r=-0.205, P=0.006), and spherical-like (r=-0.171, P=0.022) aberrations [7].
• INTERVENTION: Six patients with exacerbation of granular corneal deposits after LASIK were examined for TGFBI mutations by polymerase chain reaction sequencing of DNA [8].
• LASIK and PRK malpractice predictors [9].
• PARTICIPANTS: Five hundred consecutive eyes of 268 patients undergoing primary LASIK procedures by one surgeon utilizing the Moria LSK One microkeratome and VISX Star S-2 excimer laser [10].

Chemical compound and disease context of Keratomileusis, Laser In Situ

• PARTICIPANTS: Two thousand four hundred eighty-five eyes (1306 patients) underwent LASIK surgery for myopia, hyperopia, or astigmatism using either the Summit Apex Plus or the Alcon LADARVision excimer laser systems [11].
• Topical intrastromal steroid during laser in situ keratomileusis to retard interface keratitis [12].
• Valacyclovir inhibition of recovery of ocular herpes simplex virus type 1 after experimental reactivation by laser in situ keratomileusis [13].
• Methicillin-resistant Staphylococcus aureus keratitis after laser in situ keratomileusis [14].
• METHODS: In a DLK challenge model, laser in situ keratomileusis flaps were created by a microkeratome in rabbit eyes (n = 10 per group) and the stromal beds were treated with 1 drop of Ciloxan (ciprofloxacin 0.3%), Ocuflox (ofloxacin 0.3%), balanced salt solution (BSS), or Pseudomonas aeruginosa endotoxin before flap closure [15].

Biological context of Keratomileusis, Laser In Situ

• CONCLUSIONS: The LASIK method used in this study showed stability of manifest refraction and adequate uncorrected central visual acuity in a large percentage of patients with myopia up to -15.00 D [2].
• PURPOSE: To report the ocular manifestations and clinical course of eyes developing interface fluid after laser in situ keratomileusis (LASIK) surgery from a steroid-induced rise in intraocular pressure [16].
• SETTING: Alicante Institute of Ophthalmology, University of Alicante School of Medicine, Alicante, Spain. METHODS: This prospective study comprised 143 eyes (94 patients) that had LASIK with the Chiron Automated Corneal Shaper and the VISX 20/20 excimer laser using a multizone profile and a sutureless hinged corneal flap technique [17].
• PURPOSE: To compare the effects of a topical nonsteroidal anti-inflammatory agent, diclofenac, and prednisolone acetate on wound healing, postoperative inflammation, and other clinical parameters in laser in situ keratomileusis (LASIK) patients [18].
• CONCLUSIONS: The histology from the short pulse mid-infrared optical parametric oscillator laser at 2.94 microm was comparable to the 193-nm excimer with a smooth, damage-free, ablation zone when performing PRK and LASIK [19].

Anatomical context of Keratomileusis, Laser In Situ

• CONCLUSIONS: LASIK with or without brimonidine did not affect the structure or function of the parameters of the optic nerve studied [20].
• PURPOSE: To assess by in vivo confocal microscopy the modifications of the corneal stroma after laser in situ keratomileusis (LASIK) for myopia [21].
• Clinical outcome of wavefront-guided laser in situ keratomileusis in eyes with moderate to high myopia with thin corneas [22].
• After LASIK, the central epithelium on the corneal flap up-regulated COX-2 at 1 and 2 weeks; it returned to negative at 4 weeks [23].
• PURPOSE: To determine the presence of anterior chamber flare and cells after laser in situ keratomileusis (LASIK) for the correction of myopia [24].

Associations of Keratomileusis, Laser In Situ with chemical compounds

• INTERVENTION: All patients received a one-pass, multizone excimer laser ablation as part of either a PRK or LASIK procedure using the Summit Apex excimer laser [25].
• METHODS: Two cases of steroid-induced glaucoma after LASIK were selected [26].
• Flap rose bengal staining resolved by 6 months after LASIK in most affected patients [27].
• Evaluation of neuroprotective qualities of brimonidine during LASIK [20].
• METHODS: From September 28, 1999, to November 4, 1999, 39 eyes of 20 consecutive patients had a single drop of brimonidine tartrate 0.2% instilled into their operative eye(s) before LASIK [28].

Gene context of Keratomileusis, Laser In Situ

• CONCLUSIONS: Significant decreases in IOP were recorded by GAT after LASIK for myopia [29].
• METHODS: LASIK was performed using a VISX Star Excimer Laser (Santa Clara, CA) [30].
• METHODS: Four patients received LASIK using a Schwind Supratome (Schwind, Kleinostheim, Germany) and a MEL 70 G-Scan excimer laser (Asclepion, Jena, Germany) and were examined over the course of 1 year using slit-lamp and in vivo confocal microscopy [31].
• METHODS: Consecutive patients who underwent LASIK in the study range with the VISX Star laser were evaluated for early (approximately 1 month) and late (after 9 months) outcomes [32].
• Avellino corneal dystrophy after LASIK [8].

Analytical, diagnostic and therapeutic context of Keratomileusis, Laser In Situ

• Photorefractive keratectomy versus laser in situ keratomileusis: comparison of optical side effects. Summit PRK-LASIK Study Group [33].
• CONCLUSION: Retreatment for low amounts of residual myopia performed by lifting the original flap within the first year after surgery after myopic LASIK is safe, effective, and predictable [34].
• Corneal topography of photorefractive keratectomy versus laser in situ keratomileusis. Summit PRK-LASIK Study Group [35].
• OBJECTIVE: To compare refractive performance and safety of laser in situ keratomileusis (LASIK) and Artisan phakic intraocular lens (PIOL) for moderately high myopia [36].
• Optical coherence tomography evaluation of the corneal cap and stromal bed features after laser in situ keratomileusis for high myopia and astigmatism [37].

References